STAT+: Using AI to design small molecule drugs is tough. Here are five companies trying to crack the code
STAT
DECEMBER 3, 2024
Ian Quigley was employee #13 at AI drug company Recursion until 2021, when he quit and turned the basement of his Utah home into a lab to develop AI models for predicting which proteins small molecule drugs might target — a tool he and co-founder Andrew Blevins found was missing during their time at Recursion. When he was setting up the lab, Quigley ordered an Illumina DNA sequencer that the delivery person had wanted to leave on his porch.
Let's personalize your content